Sector News

Shire considers takeover of Swiss biotech group Actelion -Sunday Times

June 8, 2015
Life sciences
(Reuters) – Pharmaceutical company Shire is considering a 12 billion pound ($18.32 billion) takeover of Actelion Ltd Europe’s biggest biotech firm, Britain’s Sunday Times newspaper reported, citing unnamed sources.
 
An informal approach by Shire was rebuffed several weeks ago, the newspaper said, citing financial industry sources.
 
Shire was willing to pay 160 Swiss francs a share for Actelion, the sources said, a hefty premium to the stock’s Friday closing price of 132 francs.
 
Asked by Reuters for comment, a spokeswoman for Shire said the company did not comment on speculation. An Actelion spokesman said the company did not comment on market rumours.
 
Earlier this year, Actelion raised its full-year guidance after strong sales of its new heart and lung drug helped its first-quarter earnings exceed analysts’ estimates.
 
At the time, the company’s chief executive told Reuters it had not received any outside interest to buy the company.
 
In April, Shire reported a better-than-expected 20 percent rise in first-quarter earnings, helped by the launch of the first drug to treat binge eating disorder.
 
($1 = 0.6549 pounds) (Reporting by William James; additional reporting by Joshua Franklin in Zurich; editing by Jane Merriman and Jason Neely)

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.